Genitourinary videos
Round-ups, expert picks and interviews, newest first.
October 2025
IMvigor011and 2 moreDr. Gil MorganDay 4 round-up: IMvigor011, DYNAMIC-III, FORTITUDE-101
Dr. Gil Morgan. Daily round-up. Day 4. October 21, 2025.
RC48-C016CAPItello-281and 3 moreDr. Gil MorganDay 3 round-up: the top five trials
Dr. Gil Morgan. Daily round-up. Day 3. October 21, 2025.
RAMPARTKEYNOTE-905and 3 moreDr. Gil MorganDay 2 round-up: five practice-changing trials
Dr. Gil Morgan. Daily round-up. Day 2. October 21, 2025.
EMBARKCAPItello-281PETRANHADr. Gil MorganProstate cancer: EMBARK, CAPItello-281, PETRANHA
Dr. Gil Morgan. Expert pick. October 21, 2025.
InterviewDr. Silke GillessenRadioligand therapy in prostate cancer
Dr. Silke Gillessen. Interview. October 21, 2025.
RAMPARTO3AOPTICDr. Brian RiniKidney cancer: RAMPART, O3A and OPTIC
Dr. Brian Rini. Expert pick. October 21, 2025.
OPTIC RCCDr. Brian RiniOPTIC RCC: a biomarker-selected combination
Dr. Brian Rini. Expert pick. October 21, 2025.
DISCUSDr. Enrique GrandeDISCUS (LBA 109): three or six cycles before avelumab
Dr. Enrique Grande. Expert pick. October 21, 2025.
IMvigor011Dr. Tom PowlesIMvigor011: ctDNA after cystectomy
Dr. Tom Powles. Expert pick. October 21, 2025.
June 2025
Expert pickDr. Natalia GandurProstate cancer at ASCO 2025
Dr. Natalia Gandur. Expert pick. June 3, 2025. In Spanish.
- InterviewDr. Miguel Zugman
CBM588 with nivolumab and ipilimumab in kidney cancer
Dr. Miguel Zugman. Interview. June 3, 2025.
CheckMate 214Dr. Brian RiniCheckMate 214: the nine-year final results
Dr. Brian Rini. Interview. June 3, 2025.
Expert pickDr. Natalia GandurMetastatic castration-resistant prostate cancer at ASCO 2025
Dr. Natalia Gandur. Expert pick. June 3, 2025. In Spanish.
- InterviewDr. Marc Machaalani
KIM-1 in renal cell carcinoma
Dr. Marc Machaalani. Interview. June 3, 2025.
Bladder cancerDr. Brian RiniBladder cancer: antibody-drug conjugates, today and tomorrow
Dr. Brian Rini. Interview. June 3, 2025.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.



